-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-517140-65-00
9
2025-10-23
Multiple Myeloma (MM).
-
2024-516924-32-00
5
2025-10-17
Neovascular Age-Related Macular Degeneration (nAMD)
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
-
2024-519875-24-00
5
2025-09-26
Carcinoid syndrome
-
2024-517745-14-00
4
2025-09-24
Multiple Sclerosis Spasticity
-
2025-520740-16-00
5
2025-09-19
Primary Aldosteronism defined by excess aldosterone secretion
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-519814-29-00
4
2025-09-12
Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2024-519152-82-00
5
2025-09-03
Relapsed/Refractory Follicular Lymphoma
-
2023-509390-23-00
1
2025-08-29
X-linked hypophosphatemia.
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2024-519191-90-00
4
2025-07-02
Immunoglobulin Light-Chain (AL) Amyloidosis
-
2024-513683-25-00
4
2025-06-30
Patellofemoral osteoarthritis
-
2024-516020-33-00
4
2025-06-26
Grave’s Disease
-
2024-519219-32-00
5
2025-06-23
Heart Failure With Reduced Ejection Fraction
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-517545-13-00
11
2025-06-04
Neovascular Age-Related Macular Degeneration
-
2023-509547-27-00
5
2025-05-22
Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)